LRRK2 and Parkinson disease: To further demonstrate the ability of LRRK2 pharmacological inhibition to mitigate neuroinflammatory effects in vivo, we investigated the neuroinflammation and toxicity caused by intracerebral injection of AD- and PD-related aggregates in mice after intraperitoneal administration of two different LRRK2 inhibitors (as reported in the schematic Figure 2).